GlassScriptPhysician profile
Anil Purohit
NPI 1447415211
$172,361.35
in general payments reported to CMS, 2019-2025
27 companies · $94K in 2025
The $94K reported for 2025 was more than what 97% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $30.34 · 2021: $58.55 · 2022: $712 · 2023: $13K · 2024: $64K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166K · Travel and Lodging: $2,463 · Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $165,625.00 |
| Travel and Lodging | $2,462.96 |
| Food and Beverage | $2,334.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $166,565.12 | 2019-2025 | General - Ep, Ingevity+, Watchman Access System |
| Abbott Laboratories | $2,639.56 | 2019-2025 | Ensite, Ensite Precision, Jot Dx |
| Novartis Pharmaceuticals Corporation | $877.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $439.75 | 2022-2025 | Wainua, Farxiga, Lokelma |
| Pfizer INC. | $296.44 | 2019-2025 | |
| Medtronic Vascular, INC. | $252.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.22 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.79 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $129.19 | 2022-2025 | Wegovy |
| Bridgebio Pharma, INC. | $122.64 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $114.24 | 2024-2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.69 | 2022-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $98.08 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $82.10 | 2022-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $62.62 | 2024 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.19 | 2022-2023 | Verquvo |
| Daiichi Sankyo INC. | $45.12 | 2022-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $30.66 | 2022-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $23.70 | 2024 | Assure Wcd |
| Laborie Medical Technologies Corp. | $23.59 | 2024 | Endosheath Technology |
| Smith+Nephew, INC. | $23.02 | 2021 | |
| Scpharmaceuticals INC. | $22.67 | 2025 | |
| Mannkind Corporation | $20.96 | 2025 | |
| Edwards Lifesciences Corporation | $19.52 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $18.11 | 2024 | Nexletol |
| Atricure, INC. | $16.36 | 2019 | |
| Baxter Healthcare | $15.08 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Purohit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.